NCT07148245View on ClinicalTrials.gov

Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma

Not yet recruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Cutaneous MelanomaCutaneous Melanoma, Stage IIICutaneous Melanoma by AJCC V7 StageCutaneous Melanoma, Stage IV
Interventions
PROCEDURE

Blood Sample

Blood samples will be collected

OTHER

Health Related Quality of Life Questionnaires (HRQoL)

Participants may be given HRQoLs during the course of data collection

OTHER

Medical Chart Review

Participants will undergo medical charts review during the course of data collection

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT07148245 - Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma | Biotech Hunter | Biotech Hunter